Bilix Co., Ltd. news

The Korea Health Industry Development Institute (KHIDI) announced on the 31st that it held the `China Pharmaceutical Bio Investment Briefing (IR)` on the 20th, where domestic pharmaceutical companies introduced their technologies to Chinese investors. This event was jointly held with the Shanghai office of NH Investment & Securities. 10 domestic companies made IR presentations.

KISA

Bilirubin, which causes jaundice in humans, has been in the spotlight as an anti-inflammatory substance since the 1930s. The phenomenon that rheumatoid inflammation disappears when a patient with rheumatoid arthritis suffers from jaundice was discovered by Philip Hench, a professor at the Mayo Clinic in the United States, who was awarded the Nobel Prize in Physiology or Medicine. Attempts to drug bilirubin have been mad

1 Establishment of new drug pipeline with bilirubin platform technology
Securing global competitiveness by increasing corporate value
“I want to give hope to those who are living a difficult life with an incurable disease”

[IB Tomato Lim Seong-ji] “The new drug development industry is a specialized area that is difficult for ordinary investors and shareholders to understand, and it is difficult

[IB Tomato Reporter Lim Seong-ji] “The new drug development industry is a specialized area that is difficult for general investors and shareholders to understand, and it is difficult to deliver accurate information even when publicly available. The bad examples of some companies that have been inflated even with content are hindering the development of the Korean pharmaceutical and bio industry. Vilix will devote

Interest in bilirubin is high worldwide. This is because bilirubin has already received attention as a substance that has strong antioxidant effects and immunomodulatory effects through 30,000 papers from several decades ago. However, there were clear limitations in developing it as a new drug. This is because it is extremely hydrophobic, insoluble in water.